arrow
L

Luis Rivera

research institute for tropical medicine - philippines
H指数:17
被引数:2,085

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Retrospective Analysis of Blood Biomarkers of Neurological Injury in Human Cases of Viral Infection and Bacterial Sepsis

人类病毒感染和细菌性败血症患者神经系统损伤血液生物标志物的回顾性分析

2024-09-102
PRE
Efficacy and Safety of a Tetravalent Dengue Vaccine (TAK-003) in Children With Prior Japanese Encephalitis or Yellow Fever Vaccination
2024-04-294
OAAI
Real-time RT-PCR for Venezuelan equine encephalitis complex, Madariaga, and Eastern equine encephalitis viruses: application in human and mosquito public health surveillance in Panama

委内瑞拉马脑炎复合物,Madariaga和东部马脑炎病毒的实时rt-pcr: 在巴拿马的人类和蚊子公共卫生监测中的应用

2023-12-192
OAAI
Three-year Efficacy and Safety of Takeda's Dengue Vaccine Candidate (TAK-003)
2021-10-04143
OAAI
Association Between Hemagglutination Inhibition Antibody Titers and Protection Against Reverse-Transcription Polymerase Chain Reaction-Confirmed Influenza Illness in Children 6-35 Months of Age: Statistical Evaluation of a Correlate of Protection
2021-09-255
OAAI
Efficacy of a Dengue Vaccine Candidate (TAK-003) in Healthy Children and Adolescents 2 Years after Vaccination
2020-12-1565
OAAI
Safety and immunogenicity of a tetravalent dengue vaccine in children aged 2-17 years: a randomised, placebo-controlled, phase 2 trial
LANCET
IF88.5
2020-05-0165
PREAI
Efficacy of a Tetravalent Dengue Vaccine in Healthy Children and Adolescents
2019-11-21237
OAAI
Impact of Maternal Antibody on the Immunogenicity of Inactivated Polio Vaccine in Infants Immunized With Bivalent Oral Polio Vaccine: Implications for the Polio Eradication Endgame

母源抗体对二价口服脊髓灰质炎疫苗免疫婴儿的灭活脊髓灰质炎疫苗免疫原性的影响: 对脊髓灰质炎根除结局的影响

2018-10-3016
OAAI
Prevention of vaccine-matched and mismatched influenza in children aged 6-35 months: a multinational randomised trial across five influenza seasons
2018-05-0151
OAAI
Immunogenicity and safety of one versus two doses of tetravalent dengue vaccine in healthy children aged 2-17 years in Asia and Latin America: 18-month interim data from a phase 2, randomised, placebo-controlled study
2018-02-0164
PREAI
Immunogenicity and safety of three aluminium hydroxide adjuvanted vaccines with reduced doses of inactivated polio vaccine (IPV-Al) compared with standard IPV in young infants in the Dominican Republic: a phase 2, non-inferiority, observer-blinded, randomised, and controlled dose investigation trial
2017-07-0112
OAAI
Vaccine for Prevention of Mild and Moderate-to-Severe Influenza in Children

预防儿童轻度和中度至重度流感的疫苗

2013-12-26113
OAAI